Skip to main content
Premium Trial:

Request an Annual Quote

Link Technologies Inks Licensing Deal with RiboTask

NEW YORK (GenomeWeb News) – Reagents maker Link Technologies said today that it will sell RiboTask's nucleic acid monomers, under a new license agreement.

Link, a Scottish company, will make and commercialize RiboTask's unlocked-nucleic acid (UNA) monomer phosphoramadite reagents, which are used to enable fine-tuning of oligonucleotide stability in siRNA gene silencing and other applications.

Patents for the therapeutic use of UNA oligonucleotides are held by MDRNA, according to Link.

Financial terms of the agreement were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more